Study guide
11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
Key Takeaways Explain This Topic AI
CMS Conditions of Participation require hospital drugs to be prepared and administered under federal and state law and accepted standards of practice (42 CFR 482.25), and require infection prevention and antibiotic stewardship programs (42 CFR 482.42). Surveyors treat USP <797> as an accepted compounding standard.
The Joint Commission surveys medication preparation under its Medication Management standards. Since January 1, 2026, its National Performance Goals (which replaced the National Patient Safety Goals for hospitals) still require labeling of all medications and solutions on and off the sterile field, and it offers an optional Medication Compounding Certification.
CDC injection safety guidance limits single-dose vials to one patient. Multiple-dose vials should be dedicated to one patient whenever possible; if used for more than one, they stay in a centralized medication area.
ASPEN's parenteral nutrition safety recommendations cover standardized order and label formats, pharmacist order review, compounding, filters (1.2 µm for lipid-containing PN) and monitoring.
When standards overlap, follow the most stringent applicable requirement. USP chapters are minimums, and state law or accreditation standards may add to them.
Last updated: September 2026
11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
The BCSCP outline names USP, FDA, CMS, CDC, ASPEN and TJC in task 3B4. USP chapters and FDA law are covered in 1.2 and 11.1-11.2. This section covers the other standard-setters that shape a sterile compounding program, and how their requirements fit together.
CMS: Conditions of Participation
The Centers for Medicare & Medicaid Services (CMS) sets the Conditions of Participation (CoPs) a hospital must meet to bill Medicare and Medicaid. State survey agencies and CMS-approved accreditors, such as The Joint Commission, check compliance.
Pharmaceutical services, 42 CFR 482.25: Drugs and biologicals must be controlled and distributed under federal and state law and accepted standards of practice , and compounding is done by or under the supervision of a pharmacist. CMS interpretive guidance treats USP <797> as the accepted professional standard for sterile compounding, so gaps against USP <797> can become hospital survey deficiencies.
Infection prevention and control and antibiotic stewardship, 42 CFR 482.42: Hospitals must run active infection prevention and antibiotic stewardship programs. CSP-related infections and CLABSI surveillance fall within them.
Other provider types, such as ambulatory surgery centers (42 CFR Part 416) and home health agencies, have their own CoPs that also reach medication preparation and infection control.
Serious CoP deficiencies can end in termination of Medicare participation, which gives hospital leaders a strong reason to fund compounding compliance.
The Joint Commission (TJC)
Area What TJC expects
Medication Management (MM) standards Safe medication preparation, including sterile compounding in appropriate environments with proper technique; labeling; storage; high-alert drug safeguards
National Performance Goals (NPGs) Since January 1, 2026 , the NPG chapter has replaced the National Patient Safety Goals (NPSGs) for hospitals and critical access hospitals. The medication goals keep the long-standing requirements, formerly NPSG.03.04.01 and 03.05.01, to label all medications, containers and solutions on and off the sterile field and to reduce harm from anticoagulant therapy
- Infection control standards Surveillance, prevention and outbreak response, linked to compounding practices
- Survey method Tracers that follow patients and processes, with direct observation (see 10.7)
Medication Compounding Certification An optional certification for organizations that compound, built on USP <795>, <797> and <800>
CDC: infection prevention guidance
Injection safety (Core Infection Prevention Practices and the One & Only Campaign):
- use a new needle and syringe for every injection;
- single-dose vials are for one patient ;
- multiple-dose vials should be dedicated to one patient whenever possible;
if a multiple-dose vial must be used for more than one patient, keep it in a centralized medication area and never take it into the immediate patient treatment area.
Guidelines for the Prevention of Intravascular Catheter-Related Infections (2011, with later updates): maximal sterile barriers at insertion, chlorhexidine-alcohol skin antisepsis, hub disinfection, prompt removal of unneeded lines, and hang times, for example completing lipid emulsion infusions within 12 hours and PN within 24 hours (see 5.4).
NIOSH (part of CDC) publishes the hazardous drug list that USP <800> relies on (see 6.4).
CDC also investigates compounding-linked outbreaks, as it did for the 2012 NECC outbreak with 753 cases and 64 deaths.
ASPEN: parenteral nutrition safety
The American Society for Parenteral and Enteral Nutrition (ASPEN) publishes PN safety consensus recommendations and clinical guidelines that pharmacists apply every day:
Standardized PN ordering (order templates, units per day or per kilogram) and a standardized PN label format that matches the order
Pharmacist review of every PN order for dose, compatibility and access
Compounding practices: validated ACD sequences, calcium gluconate as the preferred calcium salt, calcium-phosphate solubility checks, and verifying the aqueous phase before lipid is added in total nutrient admixtures
Filters: 1.2 µm for lipid-containing PN and 0.2 µm for dextrose-amino acid PN
Monitoring and special risks: refeeding syndrome (2020 consensus), glucose, electrolytes, triglycerides, liver tests
ASHP and ISMP
ASHP guidelines on compounding sterile preparations, handling hazardous drugs, preventing chemotherapy errors and managing drug shortages. These are practice standards that surveyors and courts treat as benchmarks.
ASHP Standardize 4 Safety: national standard concentrations for continuous infusions and compounded oral liquids (see 9.7).
ISMP: guidelines for safe preparation of compounded sterile preparations, Targeted Medication Safety Best Practices (for example vinca alkaloids in minibags), and high-alert medication lists (see 9.4).
State boards and national model rules
State boards adopt USP chapters by reference, sometimes with changes or additions such as separate sterile compounding permits, nonresident pharmacy requirements, reporting rules or technician ratios. The NABP Model Act gives states model language. Always check your state's current rule.
When standards overlap
Apply the most stringent requirement that applies. For example, if USP <797> requires surface sampling monthly and the state requires it weekly, sample weekly. If an accreditor requires a label element that USP does not, add it. USP chapters are minimum standards, and stricter state law, CoPs, accreditation standards and the facility's own SOPs are layered on top.